Clinical trials: Elevated PSA
Elevated PSA, Prostate Cancer
Functional and Morphologic MRI in the Detection of Prostate Cancer in Patients With Prior Negative Biopsy
Prostate specific antigen (PSA) and digital rectal exam (DRE) are used to screen for prostate cancer. Patients with abnormal DRE or elevated PSA undergo transrectal ultrasound guided biopsy (TRUS-Bx).
- Trial name
- NCT00242060
- Testing
- MRI
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
- Trial name
- NCT03471650
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who…
- Trial name
- COMPOSITION (NCT07298265)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Adenocarcinoma of the Prostate, Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer.
- Trial name
- NCT00165399
- Testing
- Docetaxel, Estramustine, Casodex
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
Men who have Prostate Specific Antigen (PSA) recurrence with low PSA levels and long doubling times do not require immediate treatment with androgen deprivation therapy and may be safely observed.
- Trial name
- NCT01521949
- Testing
- Acai Juice Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Colorado, Denver
Neoplasms, Prostate
Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA
Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, will be treated with the P501-AS15 vaccine as out-patients.
- Trial name
- NCT00148928
- Testing
- P501-AS15 vaccine
- Where
- 8 sites in Belgium, France
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Recurrent Prostate Carcinoma, Stage I Prostate Cancer
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from…
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00108732
- Testing
- Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are…
- Trial name
- NCT01317199
- Testing
- Muscadine Plus Grape Skin Extract, Low-dose MPX, High-dose MPX
- Where
- 8 sites in United States
- Volunteers
- 143 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer
This study is an open-label extension to the double-blind GUP-0205-1 and double-blind extension GUP-0205-1XX studies. High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical…
- Trial name
- NCT00731848
- Testing
- pomegranate liquid extract
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roll International Corporation
Prostate Cancer
LIpitor and biGuanide to Androgen Delay Trial
This study is a randomized trial examining the administration of a combination of biguanide metformin and atorvastatin ("Lipitor") to men who are experiencing rising prostate-specific antigen (PSA) levels, despite having…
- Trial name
- LIGAND (NCT02497638)
- Testing
- Metformin, Atorvastatin
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Prostate Cancer, BRCA Mutation
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6…
- Conditions
- Prostate Cancer, BRCA Mutation, Mismatch Repair Gene Mutation, Genetic Predisposition to Disease
- Trial name
- NCT00261456
- Testing
- PSA test, Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 3,500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer.
- Trial name
- NCT00702923
- Testing
- Bicalutamide and CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (tremelimumab), Bicalutamide, CP-675,206
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body.
- Trial name
- NCT00685633
- Testing
- bicalutamide, enzastaurin hydrochloride
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
The primary objective of this study is to evaluate the effect of erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen deprivation therapy.
- Trial name
- NCT00148772
- Testing
- Erlotinib (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Prostate Cancer
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Radical prostatectomy is used to treat early prostate cancer in otherwise well men, but is followed by later cancer relapse in 1 in 4 cases.
- Trial name
- NCT00258765
- Testing
- Zoledronic Acid, Docetaxel
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy
Prostate cancer is currently the second most common cause of cancer death in men in Western countries. Lymphadenectomy is the gold standard procedure for staging pelvic lymph node and is classically indicated in intermediate and…
- Trial name
- LFD (NCT01812902)
- Testing
- Radical Prostatectomy
- Where
- Brazil
- Volunteers
- 260 people
- Sponsor
- University of Sao Paulo
Prostate Cancer
A Registry for Patients Treated on the Clinical Trial TAX 3503
The purpose of this study is to continue follow-up on patients who were treated on the study called TAX 3505 (MSK IRB #07-101). The sponsor of this study, has decided to end the study early, before all patients have completed all…
- Trial name
- NCT01813370
- Testing
- No intervention
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
ArtemiCoffee in Patients With Rising PSA
Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical progression years after…
- Trial name
- NCT05478239
- Testing
- ArtemiCoffee
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zin W Myint
Hypofractionated Dose, Prostate Cancer Patients
Hypo Fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer
The aim of the study is 1. Statistical evaluation of patients' characteristics who have intermediate \& high risk localized prostate cancer. 2.
- Trial name
- NCT07489729
- Testing
- Hypofractionated Intensity-Modulated Radiation Therapy, Conventional Intensity-Modulated Radiation Therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University